alexa Comorbidities in Transsexual Patients under Hormonal Tr
ISSN: 2161-038X

Reproductive System & Sexual Disorders: Current Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Comorbidities in Transsexual Patients under Hormonal Treatment Compared to Age- And Gender-Matched Primary Care Comparison Groups

María Ángeles Bazarra-Castro1*, Caroline Sievers1, Stephany Fulda2, Jens Klotsche3, Lars Pieper3, Hans-Ulrich Wittchen3 and Günter Karl Stalla1

1Clinical Neuroendocrinology Group, Max Planck Institute of Psychiatry, Munich, Germany

2Clinical Sleep Research Group, Max Planck Institute of Psychiatry, Munich, Germany

3Institute of Clinical Psychology and Psychotherapy, Technische Universitaet Dresden, Dresden, Germany

*Corresponding Author:
María Ángeles Bazarra-Castro MD
Max-Planck-Institut für Psychiatrie
Endokrinologische Ambulanz, Kraepelinstraße 2-10
80804 Munich, Germany
Tel: +49-089-30622-605
Fax: +49-089-30622-7460
E-mail: [email protected]

Received date: November 21, 2011; Accepted date: December 16, 2011; Published date: December 18, 2011

Citation: Bazarra-Castro MA, Sievers C, Fulda S, Klotsche J, Pieper L, et al. (2012) Comorbidities in Transsexual Patients under Hormonal Treatment Compared to Age- And Gender-Matched Primary Care Comparison Groups. Reproductive Sys Sexual Disord 1:101. doi:10.4172/2161-038X.1000101

Copyright: © 2011 Bazarra-Castro MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Background: There is limited data on safety aspects of hormonal treatment in transsexual patients and clinical trials are lacking. We aimed at evaluating the long-term hormonal treatment in transsexual patients. Patients: 95 transsexuals (37 female-to-male (FMT) and 58 male-to-female transsexuals (MFT)) treated between 1996 and 2007 were compared to an age- and gender-matched primary care patient group from the DETECT-cohort (matching 1:3). Results: Compared to age-matched control groups, we did not observe a higher prevalence of lifetime cardiovascular, endocrine or tumoural comorbidities. FMT showed a lower prevalence of endocrine diseases (FMT to females, p=0.008 and FMT to males, p=0.033). MFT showed a lower prevalence of cardiovascular diseases (MFT to females, p=0.005 and MFT to males, p<0.001) and endocrine diseases (MFT to females p<0.001 and MFT to males, p<0.001). Conclusion: There is no indication of an increased risk associated with HT in transsexual patients in Germany

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version